SECTOR:

Other therapeutics

FUND/VEHICLE:

Pivotal US

INVESTMENT DATE:

2018

GEOGRAPHY:

North America

STATUS CURRENT/FORMER INVESTMENT:

Existing

WEBSITE:

Inozyme is a biotechnology company committed to developing novel medicines for the treatment of rare metabolic diseases of calcification. The company was founded in 2016 with technology licensed from Yale University.